Literature DB >> 27460076

The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.

Zheng Li, Matthew S Block, Robert A Vierkant, Zachary C Fogarty, Stacey J Winham, Daniel W Visscher, Kimberly R Kalli, Chen Wang, Ellen L Goode.   

Abstract

The tumor-associated inflammatory microenvironment may play a pivotal role in epithelial ovarian cancer (EOC) carcinogenesis and outcomes, but a detailed profile in patient-derived tumors is needed. Here, we investigated the expression of TLR4- and MyD88-associated markers in tumors from over 500 EOC patients using immunohistochemical staining. We demonstrate that high expression of TLR4 and MyD88 predicts poorer overall survival in patients with EOC; most likely, this is due to their association with serous histology and features of high tumor burden and aggressiveness, including stage, grade, and ascites at surgery. Combined TLR4 and MyD88 expression appears to serve as an independent risk factor for shortened survival time, even after covariate adjustment (both moderate HR 1.1 [95 % CI 0.7-1.8], both strong HR 2.1 [95 % CI 1.1-3.8], both weak as referent; p = 0.027). We reveal that in EOC tissues with elevated expression of both TLR4 and MyD88 and activated NF-κB signaling pathway, expression of hsp60, hsp70, beta 2 defensin, and HMGB1 are also enriched. In total, these results suggest that activation of TLR4/MyD88/NF-κB signaling by endogenous ligands may contribute to an inflammatory microenvironment that drives a more aggressive phenotype with poorer clinical outcome in EOC patients.

Entities:  

Keywords:  Endogenous ligands; Epithelial ovarian cancer; Myeloid differentiation primary response gene eighty-eight (MyD88); NF-κB signaling pathway; Toll-like receptor four (TLR4)

Mesh:

Substances:

Year:  2016        PMID: 27460076      PMCID: PMC5097682          DOI: 10.1007/s13277-016-5163-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

3.  Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Authors:  Martin Köbel; Steve E Kalloger; Sandra Lee; Máire A Duggan; Linda E Kelemen; Leah Prentice; Kimberly R Kalli; Brooke L Fridley; Daniel W Visscher; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Christine Chow; Roberta B Ness; Kirsten Moysich; Robert Edwards; Francesmary Modugno; Clareann Bunker; Eva L Wozniak; Elizabeth Benjamin; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; C Blake Gilks; David G Huntsman; Susan J Ramus; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-23       Impact factor: 4.254

Review 4.  Toll-like receptors: Activation, signalling and transcriptional modulation.

Authors:  Dominic De Nardo
Journal:  Cytokine       Date:  2015-04-03       Impact factor: 3.861

5.  TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.

Authors:  Michael G Kelly; Ayesha B Alvero; Rui Chen; Dan-Arin Silasi; Vikki M Abrahams; Serena Chan; Irene Visintin; Thomas Rutherford; Gil Mor
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

6.  Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer.

Authors:  Rui-Xia Guo; Yu-Huan Qiao; Yan Zhou; Liu-Xia Li; Hui-Rong Shi; Kui-Sheng Chen
Journal:  Pathol Int       Date:  2008-12       Impact factor: 2.534

7.  Expression of Toll-like receptor 4 in ovarian serous adenocarcinoma and correlation with clinical stage and pathological grade.

Authors:  Xue-Zhen Luo; Qi-Zhi He; Kai Wang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

8.  TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.

Authors:  M Szajnik; M J Szczepanski; M Czystowska; E Elishaev; M Mandapathil; E Nowak-Markwitz; M Spaczynski; T L Whiteside
Journal:  Oncogene       Date:  2009-12-10       Impact factor: 9.867

9.  Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers.

Authors:  Ki Hyung Kim; Moo Sung Jo; Dong Soo Suh; Man Soo Yoon; Dong Hun Shin; Jeong Hee Lee; Kyung Un Choi
Journal:  World J Surg Oncol       Date:  2012-09-17       Impact factor: 2.754

Review 10.  Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies.

Authors:  Maria Muccioli; Fabian Benencia
Journal:  Front Immunol       Date:  2014-07-22       Impact factor: 7.561

View more
  17 in total

1.  Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.

Authors:  Meredith L Stone; Katherine B Chiappinelli; Huili Li; Lauren M Murphy; Meghan E Travers; Michael J Topper; Dimitrios Mathios; Michael Lim; Ie-Ming Shih; Tian-Li Wang; Chien-Fu Hung; Vipul Bhargava; Karla R Wiehagen; Glenn S Cowley; Kurtis E Bachman; Reiner Strick; Pamela L Strissel; Stephen B Baylin; Cynthia A Zahnow
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-04       Impact factor: 11.205

2.  Downregulation of high mobility group box 1 enhances the radiosensitivity of non-small cell lung cancer by acting as a crucial target of microRNA-107.

Authors:  Lu Bai; Jingjing Zhang; Dongqi Gao; Chengyi Liu; Wenxin Li; Qingshan Li
Journal:  Exp Ther Med       Date:  2021-04-25       Impact factor: 2.447

3.  TLR4 Agonist and Hypoxia Synergistically Promote the Formation of TLR4/NF-κB/HIF-1α Loop in Human Epithelial Ovarian Cancer.

Authors:  Bin Zhao; Xiulong Niu; Suhui Huang; Jing Yang; Yiyi Wei; Xiujuan Wang; Junhong Wang; Yue Wang; Xiaoqin Guo
Journal:  Anal Cell Pathol (Amst)       Date:  2022-04-14       Impact factor: 4.133

4.  Osteopontin is involved in TLR4 pathway contributing to ovarian cancer cell proliferation and metastasis.

Authors:  Cong Xu; Hua Li; Miao Yin; Tao Yang; Liguo An; Guiwen Yang
Journal:  Oncotarget       Date:  2017-10-12

Review 5.  Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance.

Authors:  Aleksandra Klemba; J Karolina Purzycka-Olewiecka; Gabriel Wcisło; Anna M Czarnecka; Sławomir Lewicki; Bogdan Lesyng; Cezary Szczylik; Claudine Kieda
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

6.  MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Authors:  Matthew S Block; Robert A Vierkant; Peter F Rambau; Stacey J Winham; Philipp Wagner; Nadia Traficante; Aleksandra Tołoczko; Daniel G Tiezzi; Florin Andrei Taran; Peter Sinn; Weiva Sieh; Raghwa Sharma; Joseph H Rothstein; Teresa Ramón Y Cajal; Luis Paz-Ares; Oleg Oszurek; Sandra Orsulic; Roberta B Ness; Gregg Nelson; Francesmary Modugno; Janusz Menkiszak; Valerie McGuire; Bryan M McCauley; Marie Mack; Jan Lubiński; Teri A Longacre; Zheng Li; Jenny Lester; Catherine J Kennedy; Kimberly R Kalli; Audrey Y Jung; Sharon E Johnatty; Mercedes Jimenez-Linan; Allan Jensen; Maria P Intermaggio; Jillian Hung; Esther Herpel; Brenda Y Hernandez; Andreas D Hartkopf; Paul R Harnett; Prafull Ghatage; José M García-Bueno; Bo Gao; Sian Fereday; Ursula Eilber; Robert P Edwards; Christiani B de Sousa; Jurandyr M de Andrade; Anita Chudecka-Głaz; Georgia Chenevix-Trench; Alicia Cazorla; Sara Y Brucker; Jennifer Alsop; Alice S Whittemore; Helen Steed; Annette Staebler; Kirsten B Moysich; Usha Menon; Jennifer M Koziak; Stefan Kommoss; Susanne K Kjaer; Linda E Kelemen; Beth Y Karlan; David G Huntsman; Estrid Høgdall; Jacek Gronwald; Marc T Goodman; Blake Gilks; María José García; Peter A Fasching; Anna de Fazio; Suha Deen; Jenny Chang-Claude; Francisco J Candido Dos Reis; Ian G Campbell; James D Brenton; David D Bowtell; Javier Benítez; Paul D P Pharoah; Martin Köbel; Susan J Ramus; Ellen L Goode
Journal:  Mayo Clin Proc       Date:  2018-03       Impact factor: 11.104

7.  TLR4/MyD88 signaling determines the metastatic potential of breast cancer cells.

Authors:  Kunlin Wu; Huihao Zhang; Yajuan Fu; Youzhi Zhu; Lingjun Kong; Ling Chen; Feng Zhao; Liangfei Yu; Xiangjin Chen
Journal:  Mol Med Rep       Date:  2018-07-26       Impact factor: 2.952

8.  Cancer cell-induced neutrophil extracellular traps promote both hypercoagulability and cancer progression.

Authors:  Hye Soo Jung; JaYoon Gu; Ji-Eun Kim; Youngwon Nam; Jae Woo Song; Hyun Kyung Kim
Journal:  PLoS One       Date:  2019-04-29       Impact factor: 3.240

9.  Prognostic Biomarker-Based Identification of Drugs for Managing the Treatment of Endometrial Cancer.

Authors:  Dilraj Kaur; Chakit Arora; Gajendra Pal Singh Raghava
Journal:  Mol Diagn Ther       Date:  2021-06-22       Impact factor: 4.074

10.  A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.

Authors:  Yi-Jen Lee; Chang-Cheng Wu; Jhy-Wei Li; Chien-Chih Ou; Shih-Chung Hsu; Hsiu-Hsueh Tseng; Ming-Ching Kao; Jah-Yao Liu
Journal:  Oncotarget       Date:  2016-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.